Health Discovery Corporation (OTCBB: HDVY) is pleased to announce that Herbert A. Fritsche, Ph.D., recently retired Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas, has joined Health Discovery Corporation as Senior Vice President and Chief Science Officer, effective September 1, 2010. “We are extremely honored that Dr. Herbert Fritsche, one of the world’s leading experts on tumor biomarkers, with his vast and unique experience has agreed to become our Senior Vice President and Chief Science Officer," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "In addition to providing unparalleled scientific expertise, Dr. Fritsche will bring significant commercialization experience having been involved with every commercially available serum cancer biomarker currently in use in the United States," said Dr. Barnhill. Dr. Fritsche was a co-author of the peer-reviewed publication of Health Discovery Corporation’s Four-Gene Expression Signature for Prostate Cancer Cells Consisting of UAP1, PDLIM5, IMPDH2, and HSPD1, in UroToday International Journal (August 2009). http://www.urotoday.com/3369/urotoday_international_journal/prostate_cancer/a_fourgene_expression_signature_for_prostate_cancer_cells_consisting_of_uap1_pdlim5_impdh2_and_hspd110132009.html As previously announced, Health Discovery Corporation entered into royalty-bearing licenses for the 4-gene urine-based prostate cancer test with Quest Diagnostics Incorporated (NYSE: DGX) and Abbott Laboratories (NYSE: ABT) for development and commercialization. The Company also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories (NYSE: ABT) for development and commercialization. “I’ve long believed that Dr. Barnhill and his patented pattern recognition technology are on the cutting edge of molecular diagnostic discovery and I’m delighted to join Dr. Barnhill and his world class team of mathematicians in new discovery projects,” said Dr. Fritsche. “This is a unique and a singular professional opportunity,” said Dr. Fritsche. Dr. Fritsche continued, "I look forward to working with Dr. Barnhill and the distinguished group of world-renowned experts he has assembled to achieve the goal of advancing scientific discovery and commercializing the next generation of diagnostic markers and drug targets."